Personalized Cancer Vaccines are designed using signals from your tumor to help guide the immune system to recognize and attack cancer more effectively.
A personalized vaccine is built using individualized tumor information (such as tumor-specific markers) to help the immune system identify cancer cells more accurately.
It’s a custom “wanted poster” for your immune system—built from your tumor’s unique fingerprint.
Some personalized approaches depend on having high-quality tumor material available. Planning early can help protect the option to pursue these strategies if they become relevant.
Patients often explore personalized vaccine options when:
Availability varies by diagnosis, center, and trial access.
Typically no—often it’s part of a broader strategy determined by the oncologist.
Personalized Cancer Vaccines are created using unique signals from a patient’s own tumor to help train the immune system to recognize and attack cancer cells more effectively. After analyzing the tumor, researchers can identify specific mutations, proteins, or markers — often called neoantigens — that may help the immune system distinguish cancer from healthy tissue.
The goal is to create a more focused immune response against the cancer. Personalized cancer vaccines may also be used or studied alongside treatments like immunotherapy to strengthen the body’s ability to fight the disease.
This is another reason tissue preservation matters. High-quality cryopreserved tumor tissue may provide more opportunities for advanced analysis, vaccine development, and clinical trial matching as cancer care continues to evolve.
A personalized vaccine is built using individualized tumor information (such as tumor-specific markers) to help the immune system identify cancer cells more accurately.
It’s a custom “wanted poster” for your immune system—built from your tumor’s unique fingerprint.
Some personalized cancer vaccine approaches depend on having high-quality tumor material available for advanced analysis. These vaccines are often designed around the unique biological signals found in a patient’s own cancer cells, which means the quality and condition of the tissue directly affects what researchers are able to identify.
Once a biopsy or surgery is complete, the way tissue is handled and preserved determines whether it can be used only for standard diagnosis or whether it remains suitable for deeper testing, clinical trial screening, or future personalized vaccine development.
For patients, this means tissue preservation is not just a storage decision — it’s a future treatment-access decision. Preserving high-quality tumor material can help keep more options available as cancer science continues to advance.
Patients often explore personalized vaccine options when:
Who is this for?
Personalized cancer vaccines are an emerging area of precision oncology that may depend on high-quality tumor material to identify tumor-specific signals, also called neoantigens. These approaches are being studied across several solid tumors, with especially strong research interest in melanoma, pancreatic cancer, lung cancer, glioblastoma, and colorectal cancer.
Cancer types commonly associated with personalized vaccine research include:
Melanoma
Melanoma has been one of the most important cancers in the development of immunotherapy and personalized vaccine research.
Pancreatic Cancer
Pancreatic cancer is an area of major interest because of its aggressive nature and the need for new personalized treatment strategies.
Lung Cancer
Lung cancer is increasingly studied in connection with personalized immunotherapy, tumor-specific mutations, and vaccine-based approaches.
Glioblastoma / Brain Cancer
Glioblastoma remains difficult to treat, making it an important area for personalized vaccine and immune-based research.
Colorectal Cancer
Certain colorectal cancers may be candidates for immune-based strategies, especially when tumor biology suggests a stronger immune target.
Availability varies by diagnosis, center, and trial access. Contact Specicare to learn more.
Typically no—often it’s part of a broader strategy determined by the oncologist.
